On January 18, 2023, CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, announced positive results from a multi-site U.S. study that showed that the company’s FirstSightTM blood test is highly accurate in detecting colorectal cancer, as well as advanced adenomas. The data from this prospective study showed that CellMax’s FirstSight blood test demonstrated 92% sensitivity for colorectal cancer and 55% sensitivity for advanced adenomas at 91% specificity. This data aligns well with the 16-year follow-up of the National Polyp Study, in which investigators made the case that advanced adenomas should be a primary target of colorectal cancer screening. “Simply put, colorectal cancer is preventable; many cases that occur could have been avoided had the right screening tests been performed in a timely manner,” said Douglas K. Rex, MD, Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, Former President of the American Society for Gastrointestinal Endoscopy and Former Chair of the U.S. Multi-Society (ACG, ASGE, AGA) Task Force on Colorectal Cancer. “In order to significantly reduce the incidence of colorectal cancer, an effective and easy screening test is critical. This is why I am very enthusiastic about this data on CellMax’s FirstSight. The study demonstrated numerically better detection of advanced adenomas than the best performing commercially available fecal tests, as well as other blood tests that are currently under development and have publicly disclosed their performance.”